Skip to main
LENZ

LENZ Stock Forecast & Price Target

LENZ Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LENZ Therapeutics Inc. has successfully completed a comprehensive clinical program, including three Phase 3 trials under the CLARITY program, demonstrating strong efficacy and a favorable safety profile that positions it for a leading market role. The company is set to capitalize on a growing baseline annual spending in the ophthalmic sector, which may continue to expand into FY27 and beyond. Positive forecasts indicate that LENZ is projected to achieve profitability by 2028, highlighting the potential for significant financial advancement.

Bears say

LENZ Therapeutics Inc faces significant commercial challenges due to potential difficulty in altering established consumer behavior regarding presbyopia treatments, which could hinder market penetration. The company lacks a diversified pipeline beyond its lead product, Vizz, raising concerns about its ability to leverage a commercial infrastructure effectively. Additionally, competitive pressures from alternative therapies and risks related to generic challenges against Vizz's intellectual property may necessitate additional funding or partnerships to realize its full market potential.

LENZ has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LENZ Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LENZ Therapeutics Inc (LENZ) Forecast

Analysts have given LENZ a Buy based on their latest research and market trends.

According to 4 analysts, LENZ has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $56.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $56.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LENZ Therapeutics Inc (LENZ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.